Friday, October 30, 2009

International Stem Cell Corporation CEO Kenneth Aldrich Speaks at Stem Cells USA & Regenerative Medicine Congress

/To display this email in a browser, please click here

conference details
Day 1
Nov 17, 8:30am - 5:30pm
Day 2
Nov 18, 8:30am - 5:30pm
Pre-conference workshop:
Nov 16, 9am - 4:30pm

Register now and save 15%
Add this to my calendar

or call +1 212 379 6320
our speakers
Dr Anthony Atala
Wake Forest Institute for Regenerative Medicine
Dr Story Landis
Head of the Stem Cell Task Force
National Institute of Health
Dr Ruth McKernan
Chief Scientific Officer
Mr Paul Grayson
President & CEO
Fate Therapeutics
Dr Yukio Hasegawa
President & CEO

Dear Colleague,

Kenneth Aldrich, Chairman and Chief Executive Officer of International Stem Cell Corporation (ISCO.OB) is speaking at Stem Cells USA & Regenerative Medicine Congress on the topic of "Is there a correct business model for regenerative medicine?" and is pleased to extend a 15% discount on your registration.

> Register now and save 15%

Key topics include:

  • Funding and partnership models
  • Stem cells as tools in predicting drug toxicity
  • Stems cells as tools in drug discovery - target identification and validation
  • Novel strategies for study of disease
  • Commercialization challenges
  • Regulatory updates & strategies to overcome regulatory hurdles
  • Enhanced production & manufacturing systems
  • Big pharma perspective on future commercialization of stem cell therapeutics
  • The challenge of commercialization
  • Cardiovascular stem cell therapeutics
  • Skin, bone and hair stem cell therapeutics

> Download the brochure

Be among the following already registered to attend:

Biotec GmbH; WuXi AppTec, Inc; Healthpoint, Ltd.; University of Nebraska Medical Center; Lonza Walkersville; LifeCell Corporation; Sartorius Stedim Biotech; Baxter Healthcare Corporation; Roche; Biomade; ECBio Sa; Medeia Therapeutics Ltd; ECBio Sa; Manufacturing Technology; BD Technologies; Miltenyi Biotec GmbH; Aastrom Biosciences; BD; NFCR; Mars Innovation; Pfizer; Tarix Pathfinder Pharmaceuticals; Vitrolife Sweden AB; AstraZeneca R&D; University of Minnesota;
American Type Culture Collection; Advenced Technologies & Regenerative Medicine LLC; Invetech, Inc; Medrad, Inc; Cytograft;Theregen;GliaMed,Inc.; Roche; Txcell; BioTime;Stem Cell Therapeutics Corp.; Centocor;Cellerant Therapeutics; Genzyme; Darpha; Safeguard Scientifics; Wake Forest Institute for Regenerative Medicine; Novitas Capital; Baxter; Bay City Capital; Fate Therapeutics;Cell Seed;Proteus Venture Partners; TVM Capital; Organogenesis; The Havard Stem Cell Institute; National Institute of Health; CONNECT; Bioengineering Institute;Stratatech Corporation; Angioblast; Pfizer;Harvard Stem Cell Institute; Cellerix; Merck Research Laboratories; Athersys, Inc.; Advanced BioHealing; Tengion; Food and Drug Administration Center for Biologics Evaluation and Research; Juventas Therapeutics Inc.; Harvard Medical School; Haecker Consulating; University of Pittsburgh School of Medicine; International Stem Cell Corporation (ISCO.OB);Pervasis Therapeutics; GliaMed, Inc.; Novocell; California Stem Cell; University of Minho; Garnet BioTherapeutics; Athersys, Inc.; Drexel University College of Medicine; Advanced BioHealing; Johnson & Johnson; Panacea Biotec Limited and more!

> Learn more about the event

Will you be there to do business and strategize with senior level executives from the leading pharma, biotechs and government organizations?

> Register now and start networking!

or call +1 212 379 6320

Your voucher code is: KA
sponsored by

Created and delivered by Terrapinn

No comments:

Post a Comment